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Background: Randomized controlled trials (RCTs) in acute coronary syndrome (ACS) with oral factor Xa inhibitors have shown conflicting results. 
We conducted a meta-analysis of RCTs of oral factor Xa inhibitors to evaluate their safety and efficacy in ACS. 
Method: Five RCT [Apixaban (APPRAISE & APPRAISE-2), Riveroxaban (ATLAS ACS and ATLAS ACS2), and Darexaban (RUBY-1)] with total 20,081 
patients were included. End points included major adverse cardiovascular events (MACE), death, CV death, myocardial infarction (MI), stent 
thrombosis (ST), stroke, TIMI major bleeding, fatal bleeding, bleeding requiring medical attention (BRMA) and blood transfusion. Combined odds 
ratios (OR) and 95% confidence intervals (CI) were computed. A two-sided alpha error <0.05 was considered statistically significant. 
Results: Oral Xa inhibitors reduced MACE [OR:0.88, CI:0.79-0.98, p=0.02], CV death [OR:0.78, CI:0.65-0.94, p=0.01] and ST [OR:0.68, CI: 0.51-
0.90, p=0.007]. All death, MI & strokes were similar in both groups. Xa inhibitors group experienced higher TIMI major bleeding [OR:2.99,CI:2.08-
4.29,p<0.001] and BRMA [OR:2.19, CI:1.76-2.72, p<0.001] but no increase in fatal bleeding [OR:1.92, CI:0.13-27.36, p=0.63] and blood 
transfusion [OR:0.43,CI:0.12-1.59,p=0.21]. 
Conclusion: Oral Xa inhibitors reduce ischemic cardiovascular events and increase risk of all cause bleeding but not fatal bleeding.
 
